Trial reportJournal of substance abuse treatment2018
Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?
Trial report in Journal of substance abuse treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review.Experimental and clinical psychopharmacology · 2021Pooled it
- Extended-release injectable naltrexone for opioid use disorder: a systematic review.Addiction (Abingdon, England) · 2018Pooled it
- Impact of extended release naltrexone on health-related quality of life in individuals with legal involvement and opioid use disorders.Substance abuse · 2021Trial
- Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder.Drug and alcohol dependence · 2018Trial
- Opioid Misuse as a Predictor of Alcohol Treatment Outcomes in the COMBINE Study: Mediation by Medication Adherence.Alcoholism, clinical and experimental research · 2018Trial
- Quality of life measures in treatment for active substance misuse: a scoping review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Midazolam, methamphetamine, morphine and nicotine intake in high-drinking-in-the-dark mice.Addiction biology · 2022Article
- An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders.Drug and alcohol dependence · 2021Observational
- Pharmacotherapeutic management of co-morbid alcohol and opioid use.Expert opinion on pharmacotherapy · 2020Review
- Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes.Journal of substance abuse treatment · 2019Article
- Subtypes in patients with opioid misuse: A prognostic enrichment strategy using electronic health record data in hospitalized patients.PloS one · 2019Observational
- Alcohol use disorder and motives for prescription opioid misuse: A latent class analysis.Substance use & misuse · 2019Article
- Alcohol and Opioid Use, Co-Use, and Chronic Pain in the Context of the Opioid Epidemic: A Critical Review.Alcoholism, clinical and experimental research · 2018Review
- Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone.Journal of substance abuse treatment · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 1 country.
Funding
Abstract
backgroundExtended release naltrexone (XR-NTX) injected intramuscularly monthly has been shown to reduce relapse in persons with opioid use disorder. Baseline factors, including patients' demographics, comorbidities and lifestyle, may help identify patients who will benefit most or least from XR-NTX treatment.
methodsPotential moderators of XR-NTX's effect were examined in the largest North American randomized open-label effectiveness trial of XR-NTX. Relapse status (Yes/No) at 6-month follow-up was regressed on treatment group (XR-NTX, N=153; or Treatment-as-Usual [TAU], N=155), baseline covariates, and their two-way interaction to identify moderator effects. Baseline covariates included age, gender, summary scores for depression, suicidal thoughts, drug abuse risk, substance use, medical, psychiatric and employment status, socialization, legal and family/social issues, history of abuse and quality of life measures.
resultsAlcohol use to intoxication in the 30days before randomization was a significant moderator: during the treatment phase, those who reported being recently intoxicated before randomization to XR-NTX relapsed to opioids at a rate (56%) similar to TAU (58%), while those without alcohol intoxication in the prior 30days had a lower rate of opioid relapse (41% vs. 65%, respectively, P<0.04).
conclusionsXR-NTX appeared to work equally well across subgroups with diverse demographic, addiction, mental health and environmental characteristics, with the possible exception of working better among those without recent alcohol intoxication. These findings should be reassuring to practitioners increasingly using XR-NTX as medical addiction therapy in diverse and often vulnerable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.